Biopharm Co. Leaders Accused Of 'Grossly Excessive' Pay
A Sage Therapeutics stockholder filed a derivative lawsuit on Friday in Delaware Chancery Court, claiming the average pay for nonemployee directors at the biopharmaceutical company is "grossly excessive" and far outpaces...To view the full article, register now.
Already a subscriber? Click here to view full article